Latest news with #CRISPRTherapeutics'
Yahoo
19-05-2025
- Business
- Yahoo
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Shares of CRISPR Therapeutics have lost momentum in recent years. The company's lone marketed product isn't generating much revenue yet. That should change over time, and the biotech could notch further clinical wins. 10 stocks we like better than CRISPR Therapeutics › Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%. The gene-editing specialist has, no doubt, faced some headwinds. However, important catalysts could double its stock price by 2030. For those keeping score at home, that would amount to a compound annual growth rate of about 14.9%, well above the market's historical average returns. CRISPR Therapeutics' focus on gene editing has some advantages and disadvantages. On the one hand, its revolutionary techniques can allow researchers to create therapies for otherwise untreatable (or difficult-to-treat) conditions. CRISPR proved as much when it created and developed Casgevy, a one-time treatment that provides a functional cure for two genetic blood disorders: sickle cell disease and transfusion-dependent beta-thalassemia. CRISPR shares the rights to Casgevy together with Vertex Pharmaceuticals. On the other hand, ex vivo gene-editing treatments are complex to manufacture and administer. The process involves collecting the patient's cells, editing their genes, and reinserting them into the patient. That's why, despite being approved since late 2023, Casgevy isn't meaningfully contributing to CRISPR Therapeutics' financial results yet. But it will eventually, and at its peak, is almost certain to far exceed the $1 billion per year in sales that is the milestone for blockbuster status. There are few competing treatments for sickle cell disease and transfusion-dependent beta-thalassemia, even in the U.S. The competitive landscape looks even better for CRISPR and Vertex in several countries in the Middle East, where they have received approvals for this product. Overall, the two estimate an addressable market of 58,000 patients in the regions they are targeting. At $2.2 million per treatment course in the U.S., the opportunity looks massive. It might take time to get there, but expect CRISPR Therapeutics' sales to grow at a good clip once money starts rolling in from Casgevy, and that should happen well before the end of the decade. Casgevy's slow uptake is one reason CRISPR Therapeutics stock has not performed well in recent years. Another is that clinical progress often drives the performance of small biotechs with few or no products on the market. Some investors take their profits and leave once they achieve significant clinical and regulatory milestones. That's what happened here. CRISPR Therapeutics' shares skyrocketed in the five years following its 2016 IPO, a period during which it more than doubled. CRSP data by YCharts Though it has experienced a significant pullback since 2021, CRISPR Therapeutics could bounce back as it shows substantial pipeline progress while making commercial headway with Casgevy. The company is working on several promising candidates for which it could release data readouts as early as this year. They include CTX112 and CTX131, two potential cancer medicines. The former received the Regenerative Medicine Advanced Therapy designation from the Food and Drug Administration, a sign that it has shown promising clinical evidence in treating a serious condition. CRISPR Therapeutics should also release data from an ongoing clinical trial for CTX320, a medicine being developed to lower lipoprotein(a) levels, which can cause a range of cardiovascular problems when too high. These programs and others -- such as CRISPR's investigational functional cure for type 1 diabetes -- could make significant headway in the next five years. They might not all pan out, but even a 50% success rate in getting products to market, after the smashing success it saw by laser-focusing on Casgevy, would be a significant win for the company. In the meantime, a series of clinical wins could eventually jolt the company's shares. Of course, there is the possibility that the biotech will run into severe setbacks, and given that it only has one product on the market and remains unprofitable for now, that could send the stock down even further. CRISPR Therapeutics carries above-average risk as an investment, but for those comfortable with the volatility, it is worth initiating a small position in the stock -- it could deliver monster returns in the next five years. Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $642,582!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $829,879!* Now, it's worth noting Stock Advisor's total average return is 975% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Prediction: This Beaten-Down Stock Could Double in The Next 5 Years was originally published by The Motley Fool
CNBC
06-05-2025
- Health
- CNBC
CRISPR-based gene editing revolutionized medicine—what's next for the firm that helped develop it?
CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA sequence that is cut by an enzyme called Cas 9. It then changes or replaces that sequence with a different section of DNA. For this discovery, co-inventors Emmanuelle Charpentier and Jennifer Doudna received the Nobel Prize in Chemistry in 2020. "By our interest in the lab to find new molecules that could have a role in in the bacterium streptococcus pardonus , we came across a very neat mechanism that allows to really recognize the virus that infects the bacterium in a very, very specific minor at the level of the genome of the virus. And we exploited this natural mechanism to develop the CRISPR-Cas9 technology," Emmanuelle Charpentier said in an interview with CNBC's The Edge. In 2013, Charpentier co-founded CRISPR Therapeutics to fulfil her lifelong goal of finding cures for diseases. A decade later, the company and its partner Vertex Pharmaceuticals developed CASGEVY, a therapy to treat blood disorders beta thalassemia and sickle cell disease. "With CASGEVY, we're taking the bone marrow cells from the patient, making the edit for that particular patient and we're putting it back into the patient, and it reconstitutes the hematopoietic system of the patient. We're making a drug just for you," CRISPR Therapeutics' CEO Samarth Kulkarni told The Edge. CASGEVY is a one-time therapy that costs $2.2 million per patient and can be administrated on patients 12 years of age and older. In 2023, it became the first CRISPR-based gene editing therapy to be approved by the Federal Drug Administration. CRISPR Therapeutics currently has seven clinical and ten pre-clinical programs across oncology, autoimmune cardiovascular disease and diabetes, and is investigating next generation editing modalities. Watch the video above for the full interview with Professor Charpentier from Berlin, Germany, and a tour of CRISPR Therapeutics' facilities in Boston, Massachusetts.
Yahoo
27-03-2025
- Business
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) COO Departure Announced Following 7% Share Price Decline
CRISPR Therapeutics recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction. During the past quarter, the company's shares declined by 4.6%, a period marked by a challenging earnings report showing significant revenue drops and increased losses, which likely contributed to the recent share price performance. This downturn occurred amidst wider market concerns, including tariff announcements and broader trade policy uncertainties, which also weighed on investor sentiment, even as major indices such as the S&P 500 saw slight declines. Buy, Hold or Sell CRISPR Therapeutics? View our complete analysis and fair value estimate and you decide. AI is about to change healthcare. These 23 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Over the past five years, CRISPR Therapeutics' total shareholder return, including dividends, increased by a modest 1.77%. During this period, the company has faced substantial revenue fluctuations, including a reported revenue drop in 2024, with full-year revenues falling significantly to USD 37.31 million. The volatile revenue pattern was accompanied by substantial net losses, which grew consistently, reaching USD 366.25 million in 2024. Despite some promising product announcements, such as the FDA's RMAT designation for CTX112, these developments have not compensated for the financial pressures evident in recent earnings reports. Furthermore, CRISPR Therapeutics' performance has been weaker when compared to the broader market, with its one-year return trailing the US Market's 8.5% and the US Biotechs industry's negative returns. The company's ability to generate revenue has been a central concern, as highlighted by an equity offering in February 2024 raising approximately USD 280 million, a potential effort to shore up finances amid ongoing losses. Click here and access our complete financial health analysis report to understand the dynamics of CRISPR Therapeutics. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
22-03-2025
- Business
- Yahoo
2 Beaten-Down Stocks to Buy on the Dip
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative medical therapies. CRISPR Therapeutics' shares are down by 41% over the trailing-12-month period, while Merck's have declined by 22%. Though both companies have encountered some headwinds, there are good reasons for patient investors to initiate positions, especially at current levels. It's not hard to figure out why CRISPR Therapeutics, a gene-editing specialist, isn't performing well. Though the company earned approval for Casgevy, which treats a pair of rare blood diseases, in late 2023, it's still not generating much revenue from it. Administering gene-editing therapies is expensive and time-consuming. Furthermore, CRISPR Therapeutics will share the profits generated from Casgevy with Vertex Pharmaceuticals, with which it developed the medicine; Vertex is entitled to 60% of the program profits. Still, Casgevy is now approved in the U.S., the U.K., and the European Union, in addition to several countries in the Middle East where the market opportunity may be larger than it is in the U.S. The mid-cap CRISPR Therapeutics would have never sought approvals in all those regions -- it's far too costly to do so for a company of this size. Even if it had, it wouldn't have done it that fast. So Casgevy's target market is much bigger than it otherwise would be, thanks to CRISPR Therapeutics' partnership with Vertex. Although it isn't yet contributing much to CRISPR Therapeutics' results, Casgevy will, eventually. It costs $2.2 million per treatment course, and hardly any approved competing treatments can challenge it. Casgevy is a one-time curative option for two otherwise lifelong diseases that rob patients of years -- or decades -- of average life expectancy, and cause severe hardships and financial burdens to them and their families. Elsewhere, CRISPR Therapeutics is developing other gene-editing medicines. It's working on a functional cure for type 1 diabetes. Meanwhile its CTX112, being developed to treat B-cell malignancies, has earned the Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration. This designation is granted to and helps speed up the development of medicines that target serious or life-threatening conditions and have provided promising early evidence of efficacy. CRISPR Therapeutics has already demonstrated significant innovative abilities. Expect the company to record important clinical wins in the next few years while it ramps up sales from Casgevy. After losing more than 40% of its value over the last 12 months, the stock could generate excellent returns for patient investors. Merck's best-selling medicine is Keytruda, which has earned dozens of indications worldwide e across many different types of cancer. Last year, an investigational cancer treatment called ivonescimab performed better than Keytruda in a phase 3 clinical trial conducted in China, on patients with non-small cell lung cancer and a PD-L1 protein overexpression -- one of Keytruda's most important markets. Eventual competition from ivonescimab could eat into Keytruda's market share -- and the older medicine will run out of patent exclusivity in 2028. Last year, Merck generated revenue of $64.2 billion, up 7% compared to 2023, a solid performance for a pharmaceutical giant. Keytruda's sales were $29.5 billion, up 18% year over year; the drug accounted for about 46% of Merck's top line. That's why the market is spooked: Losing Keytruda could be a catastrophe for Merck. However, the company has long been setting up its post-Keytruda plans. Merck will first extend the medicine's patent life through a subcutaneous formulation. This version of Keytruda should earn indications across many of the original's markets, and generate decent sales well into the 2030s. Moreover, the company will seek to develop newer, better medicines. Merck signed an agreement with China-based LaNova Medicines to develop LM-299, a cancer medicine in the same category as ivonescimab. Merck also joined the search for an effective weight management medicine through a licensing agreement with Hansoh Pharma for HS-10535, a preclinical GLP-1 candidate. Merck's own newer medicines, like Winrevair, a treatment for pulmonary arterial hypertension (PAH) with a novel mechanism of action, should eventually generate over $1 billion in annual sales. The company has a deep pipeline of its own, too. Lastly, Merck is a solid dividend stock. The company's forward yield now tops 3.4%, and it has increased its payouts by 80% in the past decade. Merck's issues are real, but it's encountered similar ones before in its long and storied history and has always come out on top. It seems to have the means to do the same this time. Despite dropping by more than 20% in the past year, the stock is an excellent pick for long-term investors. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $305,226!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $41,382!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $517,876!* Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of March 18, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics, Merck, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 2 Beaten-Down Stocks to Buy on the Dip was originally published by The Motley Fool Sign in to access your portfolio
